Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096326 · ClinicalTrials.gov registry record · Phase 2
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
NCT04096326: Completed Phase 2 study, sponsored by Allergan.
NCT04096326 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 198 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04096326, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
Primary Outcome
Percentage of participants achieving a ≥ 2-grade improvement from baseline on the FWS according to investigator assessments of GL severity at maximum frown at any postintervention timepoint through Day 7 were reported. Investigators' assessments of the severity of GL at rest and maximum frown using the validated FWS was assessed using the 4-grade FWS, where 0=none, 1=mild, 2=moderate, and 3=severe. Higher scores indicate more severity. Percentages are rounded off to nearest single decimal.
Interventions
- DRUG Placebo
- DRUG AGN-151586
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2020-09-09 |
| Phase | Phase 2 |
What the finished NCT04096326 record still lists
NCT04096326 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04096326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04096326 about?
NCT04096326 is a clinical study titled "AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines". The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
What is the current status of trial NCT04096326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2019-09-26. Estimated completion is 2020-09-09.
What interventions are being tested in trial NCT04096326?
The interventions under investigation include: Placebo (DRUG), AGN-151586 (DRUG).
Who is sponsoring clinical trial NCT04096326?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04096326's enrollment target sits among peer trials
198 349th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI